Drugs online research references
Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):51-4.
Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.
Hjelm U, Kaustova J, Kubin M, Hoffner SE.
Department of Bacteriology, National Bacteriological Laboratory, Stockholm, Sweden.
The susceptibility of Mycobacterium kansasii to antibacterial agents alone and in combination was studied. Widespread resistance to ethambutol, ciprofloxacin and isoniazid was found when these drugs were tested separately. However, pronounced antibacterial effects were seen when ethambutol was tested in combination with ciprofloxacin, rifampicin or rifabutin, which corresponded to significantly decreased resistance to these drugs in combination.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1563386&dopt=Abstract
Pathol Biol (Paris). 1988 May;36(5):477-81.
[Sensitivity of 7 mycobacterial species to new quinolones]
[Article in French]
Gevaudan MJ, Mallet MN, Gulian C, Terriou P, Lagier P, de Micco P.
Laboratoire de Microbiologie, Hygiene et Epidemiologie Hospitaliere, Hopital Salvator, Marseille.
The authors have tested the sensibility to three new quinolones of forty one strains of mycobacteria belonging to seven different species. They have observed, in particular, susceptibility for the species M. tuberculosis, M. fortuitum, M. kansasii, M. marinum and M. xenopi to ciprofloxacin and ofloxacin and a limited sensibility for these same species to pefloxacin. In association with others antibiotics, amikacin, erythromycin, thienamycin, trimethoprim-sulfamethoxazole, the three have shown some additive effects and in a few cases synergistic effects.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3136429&dopt=Abstract
Antimicrob Agents Chemother. 1993 Jun;37(6):1285-8.
Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations.
Hoffner SE, Hjelm U, Kallenius G.
National Bacteriological Laboratory, Stockholm, Sweden.
Mycobacterium malmoense is an opportunistic pathogen with increasingly recognized clinical importance. It is mainly isolated in northern Europe and Great Britain, most often from patients with pulmonary infections. Conventional therapy of M. malmoense infections with antituberculosis drugs is often of limited value, and there is thus a need for improved drug regimens. The potential efficacies of new alternative drugs, such as quinolones, macrolides, amikacin, and rifabutin, are still unknown, and so is the pathogen's in vitro susceptibility to most of these drugs. In this study, we used the BACTEC system for determining the pattern of resistance of clinical M. malmoense isolates to a number of antibacterial drugs as well as their possible synergistic interactions when each of them was combined with ethambutol. The majority of the strains were resistant or moderately resistant to the drug when it was tested alone at selected concentrations. However, pronounced in vitro synergism was demonstrated for combinations of ethambutol with ciprofloxacin, amikacin, and rifampin, rendering most isolates susceptible to the combined drugs. Thus, for in vitro susceptibility testing of M. malmoense, examination of the possible synergistic effects of combined drugs also can be recommended.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8392308&dopt=Abstract
online pharmacies ||
Hair Million herbal formula for hair loss and hair growth ||
Amoxicillin ||
Tramadol ||
Paxil ||
Rx Drugs USA, Prescription Drugs Online Pharmacy ||
Zithromax ||
online pharmacy ||
Antibiotics and prescription medications online literature ||
Antibiotics